期刊文献+

乳腺癌骨转移的临床病理因素分析 被引量:2

下载PDF
导出
摘要 目的 研究与乳腺癌骨转移有关的临床、病理因素,探讨有助于预测乳腺癌骨转移的危险因素.方法 对上海市第六人民医院乳腺外科行改良根治切除术的124例乳腺癌患者的随访资料进行回顾分析,其中52例发生骨转移.探讨骨转移与年龄、绝经状况、组织学分级、肿瘤大小、腋窝淋巴结转移、ER、临床分期、HER-2、P53、肿瘤部位的关系.结果 乳腺癌骨转移好发于腰椎、胸椎、骨盆、肋骨,中位发生时间为31个月,乳腺癌骨转移的发生率为41.9%(52/124),肿瘤大小≤2cm组骨转移率30.8%,2cm<肿块≤5cm组骨转移率40.4%,>5cm组骨转移率75.0%,三组差异有统计学意义,临床分期Ⅰ-Ⅱ期组骨转移率19.8%,Ⅲ-Ⅳ期组骨转移率83.7%,二组间差异有统计学意义(P=0.000);淋巴结阴性组骨转移率21.4%,淋巴结1~3个阳性组骨转移率40.9%,淋巴结4~9个阳性组骨转移率64.3%,>10个阳性组骨转移率72.2%,四组间差异有统计学意义(P=0.000),HER-2阴性组骨转移率35.7%,HER-2阳性组骨转移率55.0%,二组间差异有统计学意义(P=0.042);而与年龄、绝经状况、组织学分级、ER、P53、肿瘤部位无明显相关性.结论 肿瘤大小、腋窝淋巴结转移、临床分期、HER-2是乳腺癌骨转移的高危因素,该类病例要开展密切随访及积极的综合治疗.
出处 《中国血液流变学杂志》 CAS 2011年第1期124-126,141,共4页 Chinese Journal of Hemorheology
基金 上海市卫生局青年科研项目(2008Y086)
  • 相关文献

参考文献10

  • 1Smid M,Wang Y,Klijn JG,et al.Genes associated with breast cancer metastatic to bone[J].J Clin Oncol,2006,24(15):2261-2267.
  • 2周建华,张清媛,陆海波,于丽娟,张立臣.乳腺癌骨转移的综合治疗(附70例临床分析)[J].中华肿瘤杂志,1997,19(4):284-286. 被引量:8
  • 3吴炅,邵志敏,沈坤炜,韩企夏,沈镇宙.乳腺癌骨转移相关的临床病理因素的研究[J].中国癌症杂志,2003,13(4):316-318. 被引量:22
  • 4Colleoni M,O'neill A,Goldhirsch A,et al.Identifying breast cancer patients at high risk for bone metastases[J].J Clin Oncol,2000,18(23):3925-3935.
  • 5石根明,王跃珍.乳腺癌骨转移的危险因素分析[J].浙江医学,2005,27(1):19-22. 被引量:12
  • 6柴枫.乳腺癌骨转移86例回顾性分析[J].实用医药杂志,2006,23(5):561-562. 被引量:1
  • 7Koopman C,Hermanson K,Diamond S,et al.Social support,life stress,pain and emotional adjustment to advanced breast cancer[J].Psychooncology,1998,7(2):101-111.
  • 8Koizumi M,Yoshimoto M,Kasumi F,et al.What do breast cancer patients benefit from staging bone scintigraphy?[J].Jpn J Clin Oncol,2001,31(6):263-269.
  • 9Coleman RE,Rubens RD,Fogelman I.Reappraisal of the baseline bone scan in breast cancer[J].J Nucl Med,1988,29(6):1045-1049.
  • 10Ro(s)ian A,Laz(a)r E,Dema A.C-erbB2 oncoprotein:prognosticmarker in breast cancer[J].Rom J Morphol Embryol,2005,46(2):99-104.

二级参考文献26

  • 1王舒,刘俊达.老年人淋巴细胞免疫功能的变化[J].中国老年学杂志,1996,16(3):167-170. 被引量:4
  • 2Mitsuru K, Masataka Y, Fujio K, et al. What do breast cancer patients benefit from staging bone scintigraphy[ J ] ? Jpn J Clin Oncol,2001,31(6) :263-269.
  • 3Colleoni M, ONeill A, Goldhirach A, et al. Identifying breast cancer patients at high risk for bone metastases[ J ]. J Clin Oncol,2000,18 (23) :3925-3935.
  • 4Mundy GR, Martin TJ. Pathophysiology of skeletal complications of cancer [ A ], Mundy GR, Martin TJ ( eds ) : Physiology and pharmacology of bone[ M ]. 1st ed Berlin: Springer-Verlag,1993:641-671.
  • 5Koyama T, Haaebe T, Tsuda H, et al.Histological factors associated with initial bone metastaaia of invaaive ductal carcinoma of the breast[J]. Jpn J Cancer Res, 1999,90 (3) :294-300.
  • 6Tsuda H, Sakamaki C, Fukutomi T, et al.Squamoid features and expression of involucrin in primary breast carcinoma associated with high histological grade, tumour cell necrosis and recurrence sites[J]. Br J Cancer, 1997,75(10) :1519-1524.
  • 7Diel U, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment[J].N Engl J Med,1998,339(3):357-363
  • 8Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices[ J ].Cancer Res, 1997 ,57( 11 ) :3890-3894.
  • 9Coleman RE, Rubens RD, Fogelman I. Reappraisal of baseline bone scan in breast cancer. J Nucl Med, 1988, 29: 1045.
  • 10Merrick MV. Evaluation and skeletal metastases. British Journal of Radiology, 1992, 65: 803.

共引文献34

同被引文献29

  • 1Uccello M, Malaguarnera G, Vacante M, et al. Serum bone sialoprotein levels and bone metastases[J]. J Cancer Res Ther, 2011, 7(2):115-119.
  • 2Zhang L, Hou X, Lu 5, et al. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study[J]. Lung Cancer, 2010, 67(1 ):114-119.
  • 3Yong M, Jensen A(), Jacobsen JB, et al. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007)[J]. Breast Cancer Res Treat, 2011, 129(2):495-503.
  • 4Reufsteck C, Lifshitz-Shovali R, Zepp M, et al. Silencing of skeletal metastasis-associated genes impairs migration of breastcancer cells and reduces osteolytic bone lesions[J]. C/in Exp Metastasis, 2012, 29(5): 441-456.
  • 5Wang J, Wang L, Xia B, et al. BSP gene silencing inhibits migration, invasion, and bone metastasis of MDA-MB-231BO human breast cancer cells[J]. PIoS One, 2013, 8(5):e62936.
  • 6Tu Q, Zhang J, Fix A, et al. Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells[J].J Cell Physiol, 2009, 218(1):135-145.
  • 7Uccello M, Malaguarnera G, Vacante M, et al. Serum bone sialoprotein levels and bone metastases[J]. J Cancer Res Ther, 2011,7(2):115-119.
  • 8He JJ, Zhi K, Liu GF. Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer[J]. Onkologie, 2011, 34(11):584-588.
  • 9Wang Y, Zhang XF, Dai J serum bone sialoprote et al. Predictive value of n and prostate-specificantigen doubling time in patients with bone metastasis of prostate cancer[J]. J Huazhong Univ Sci Technolog Med Sci, 2013, 33(4):559-62.
  • 10Rosa Mendoza ES, Moreno E, Caguioa PB. Predictors of early distant metastasis in women with breast cancer[J]. J Cancer Res C/in Oncol, 2013, 139(4):645-652.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部